Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer

Obstetrics and Gynecology

Volumn 124, Issue 5, 2014, Pages 881-885

  Erickson, Britt K ^b   Kinde, Isaac ^b   Dobbin, Zachary C ^b   Wang, Yuxuan ^b   Martin, Jovana Y ^b   Alvarez, Ronald D ^b   Conner, Michael G ^b   Huh, Warner K ^b   Roden, Richard B S ^b   Kinzler, Kenneth W ^b   Papadopoulos, Nickolas ^b   Vogelstein, Bert ^b   Diaz, Luis A ^b   Landen, Charles N ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; CANCER GRADING; CELL ISOLATION; CLINICAL ARTICLE; DNA DETERMINATION; FEMALE; GENE; HUMAN; MENSTRUAL TAMPON; MIDDLE AGED; MUTATIONAL ANALYSIS; OVARY CANCER; PELVIS TUMOR; PRIORITY JOURNAL; SOMATIC MUTATION; TP 53 GENE; TUMOR CELL; UTERINE TUBE LIGATION; CLINICAL TRIAL; CYSTADENOCARCINOMA, SEROUS; EARLY DIAGNOSIS; FEMININE HYGIENE PRODUCT; GENETICS; NUCLEOTIDE SEQUENCE; OVARIAN NEOPLASMS; PILOT STUDY; PREDICTIVE VALUE;

PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BIOMARKERS, TUMOR; CYSTADENOCARCINOMA, SEROUS; DNA MUTATIONAL ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MENSTRUAL HYGIENE PRODUCTS; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84939829262     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000484     Document Type: Article

References (7)

1. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010;221:49-56.
2. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
3. Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih Ie M, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013;5:167ra4.
4. Mingels MJ, Van Ham MA, De Kievit IM, Snijders MP, Van Tilborg AA, Bulten J, et al. Müllerian precursor lesions in serous ovarian cancer patients: using the SEE-Fim and SEE-End protocol. Mod Pathol 2014;27:1002-13.
5. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007;31:161-9.
6. Piek JM, Van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-6.
7. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectalcancer screening. N Engl J Med 2014;370:1287-97.